Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adenosine A2A Receptor (A2AR)
100%
Immune Checkpoint
100%
Pharmacological Targeting
100%
CD19 chimeric Antigen Receptor T Cells
100%
T Cells
71%
Tumor Microenvironment
42%
Chimeric Antigen Receptor T Cells (CAR-T)
28%
T Cell Activation
14%
Clinical Outcomes
14%
Antitumor Activity
14%
Hematological Malignancies
14%
Cytotoxic Activity
14%
Hypoxia
14%
Tumor Progression
14%
Therapeutic Implications
14%
Cytokine Production
14%
Adenosine
14%
Chronic Lymphocytic Leukemia
14%
Pharmacological Inhibitors
14%
Receptor Expression
14%
Clinical Setting
14%
B-cell Leukemia
14%
Immunosuppression
14%
Follicular Lymphoma
14%
Microenvironment
14%
Hematological Cancer
14%
Proliferation Ability
14%
Fully Human
14%
Hereafter
14%
Functional Assay
14%
Receptor Overexpression
14%
Tumor Relapse
14%
Restimulation
14%
Acute Lymphoblastic
14%
Adenosine Analogue
14%
Immunosuppressive Network
14%
Immunology and Microbiology
T Cell
100%
CD19
100%
Chimeric Antigen Receptor T-Cell
100%
In Vitro
100%
B Cell
16%
Cytokine Production
16%
Antineoplastic Activity
16%
Cytotoxicity
16%
Immunosuppressive Drug
16%
Target Cell
16%
Chimeric Antigen Receptor
16%
Immunosuppression
16%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Adenosine
100%
Chimeric Antigen Receptor
100%
Tumor Microenvironment
37%
Antitumor Activity
12%
Hematologic Malignancy
12%
Tumor Growth
12%
Cytotoxicity
12%
Cytokine
12%
Hypoxia
12%
Chronic Lymphatic Leukemia
12%
Immunosuppressive Agent
12%
Follicular Lymphoma
12%
B Cell Leukemia
12%
Adenosine Derivative
12%